SMMT Summit Therapeutics Inc.
Summit Therapeutics Inc. (SMMT) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
Where they traded
Last open-market purchase: June 12, 2026 , by DUGGAN ROBERT W .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Co-Chief Executive Officer | Buy | 3,810,000 | $13.12 | $50.0M | 573,883,879 | |
| Zanganeh Mahkam | Co-Chief Executive Officer | Buy | 3,810,000 | $13.12 | $50.0M | 573,883,879 | |
| DUGGAN ROBERT W | Co-Chief Executive Officer | Buy | 100,000 | $14.60 | $1.5M | 25,824,474 | |
| Zanganeh Mahkam | Co-Chief Executive Officer | Buy | 100,000 | $14.60 | $1.5M | 25,824,474 | |
| Soni Manmeet Singh 2 fills | COO and CFO | Buy | 50,000 | $14.45 | $722.3K | 3,123,603 |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.